Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has 5 years of FCF Margin data on record, last reported at 73.64% in Q2 2024.

  • On a quarterly basis, FCF Margin rose 246818.0% to 73.64% in Q2 2024 year-over-year; TTM through Jun 2025 was 81.46%, a 6601.0% decrease, with the full-year FY2024 number at 3.12%, up 325795.0% from a year prior.
  • FCF Margin reached 73.64% in Q2 2024 per FULC's latest filing, up from 2667.62% in the prior quarter.
  • Over the last five years, FCF Margin for FULC hit a ceiling of 73.64% in Q2 2024 and a floor of 8201.69% in Q1 2023.
  • A 5-year average of 1689.49% and a median of 862.35% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -733935bps in 2023, then skyrocketed 246818bps in 2024.
  • Tracing FULC's FCF Margin over 5 years: stood at 454.86% in 2020, then increased by 10bps to 409.27% in 2021, then tumbled by -538bps to 2609.49% in 2022, then dropped by -2bps to 2667.62% in 2023, then soared by 103bps to 73.64% in 2024.
  • Business Quant data shows FCF Margin for FULC at 73.64% in Q2 2024, 2667.62% in Q4 2023, and 3026.48% in Q3 2023.